Evidence map›Paper›PMID 32855419›Full record

ArticleNature communications2020

Warsaw Breakage Syndrome associated DDX11 helicase resolves G-quadruplex structures to support sister chromatid cohesion.

Janne J M van Schie, Atiq Faramarz, Jesper A Balk, Grant S Stewart, Erika Cantelli, Anneke B Oostra, Martin A Rooimans, Joanna L Parish, Cynthia de Almeida Estéves, Katja Dumic and 9 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 4 countries.

Janne J M van Schie *Section of Oncogenetics, Cancer Center Amsterdam and Department of Clinical Genetics, Amsterdam University Medical Centers, De Boelelaan 1118, 1081, HV, Amsterdam, the Netherlands.
Atiq Faramarz *Section of Oncogenetics, Cancer Center Amsterdam and Department of Clinical Genetics, Amsterdam University Medical Centers, De Boelelaan 1118, 1081, HV, Amsterdam, the Netherlands.
Jesper A BalkSection of Oncogenetics, Cancer Center Amsterdam and Department of Clinical Genetics, Amsterdam University Medical Centers, De Boelelaan 1118, 1081, HV, Amsterdam, the Netherlands.
Grant S StewartInstitute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.ORCID http://orcid.org/0000-0002-0960-3241
Erika CantelliNetherlands Cancer Institute, Division of Tumor Biology and Immunology, Amsterdam, The Netherlands.
Anneke B OostraSection of Oncogenetics, Cancer Center Amsterdam and Department of Clinical Genetics, Amsterdam University Medical Centers, De Boelelaan 1118, 1081, HV, Amsterdam, the Netherlands.
Martin A RooimansSection of Oncogenetics, Cancer Center Amsterdam and Department of Clinical Genetics, Amsterdam University Medical Centers, De Boelelaan 1118, 1081, HV, Amsterdam, the Netherlands.
Joanna L ParishInstitute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.ORCID http://orcid.org/0000-0002-7111-4211
Cynthia de Almeida EstévesDepartamento de Genetica, Hospital Militar, Montevideo, Uruguay.
Katja DumicDepartment of Pediatric Endocrinology and Diabetes, University Hospital Centre Zagreb, University of Zagreb Medical School, Zagreb, Croatia.
Ingeborg BarisicChildren's Hospital Zagreb, Center of Excellence for Reproductive and Regenerative Medicine, Medical School University of Zagreb, Zagreb, Croatia.
Karin E M DiderichDepartment of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands.
Marjon A van SlegtenhorstDepartment of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands.
Mohammad MahtabIstituto di Biochimica e Biologia Cellulare, Consiglio Nazionale delle Ricerche, Naples, Italy.ORCID http://orcid.org/0000-0001-9496-8941
Francesca M PisaniIstituto di Biochimica e Biologia Cellulare, Consiglio Nazionale delle Ricerche, Naples, Italy.
Hein Te RieleNetherlands Cancer Institute, Division of Tumor Biology and Immunology, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-0255-4042
Najim AmezianeSection of Oncogenetics, Cancer Center Amsterdam and Department of Clinical Genetics, Amsterdam University Medical Centers, De Boelelaan 1118, 1081, HV, Amsterdam, the Netherlands.
Rob M F WolthuisSection of Oncogenetics, Cancer Center Amsterdam and Department of Clinical Genetics, Amsterdam University Medical Centers, De Boelelaan 1118, 1081, HV, Amsterdam, the Netherlands. r.wolthuis@amsterdamumc.nl.ORCID http://orcid.org/0000-0002-3109-1588
Job de LangeSection of Oncogenetics, Cancer Center Amsterdam and Department of Clinical Genetics, Amsterdam University Medical Centers, De Boelelaan 1118, 1081, HV, Amsterdam, the Netherlands. j.delange1@amsterdamumc.nl.ORCID http://orcid.org/0000-0002-9002-8829
Amsterdam University Medical Centers · NLErasmus MC · NLThe Netherlands Cancer Institute · NLUniversity of Birmingham · GBCentogene (Germany) · DEUniversity Hospital Centre Zagreb · HRUniversity of Zagreb · HR

Funding

Cancer Research UK C17183/A23303Medical Research Council MR/R022011/1Medical Research Council MR/T015985/1
6 · The paper itself

Abstract

Warsaw Breakage Syndrome (WABS) is a rare disorder related to cohesinopathies and Fanconi anemia, caused by bi-allelic mutations in DDX11. Here, we report multiple compound heterozygous WABS cases, each displaying destabilized DDX11 protein and residual DDX11 function at the cellular level. Patient-derived cell lines exhibit sensitivity to topoisomerase and PARP inhibitors, defective sister chromatid cohesion and reduced DNA replication fork speed. Deleting DDX11 in RPE1-TERT cells inhibits proliferation and survival in a TP53-dependent manner and causes chromosome breaks and cohesion defects, independent of the expressed pseudogene DDX12p. Importantly, G-quadruplex (G4) stabilizing compounds induce chromosome breaks and cohesion defects which are strongly aggravated by inactivation of DDX11 but not FANCJ. The DNA helicase domain of DDX11 is essential for sister chromatid cohesion and resistance to G4 stabilizers. We propose that DDX11 is a DNA helicase protecting against G4 induced double-stranded breaks and concomitant loss of cohesion, possibly at DNA replication forks.

Indexed as

G-QuadruplexesSister Chromatid ExchangeAbnormalities, MultipleCell ProliferationDEAD-box RNA HelicasesDNA HelicasesFanconi Anemia Complementation Group ProteinsHumansMaleMiddle AgedMutation, MissenseProtein StabilityPseudogenesRad51 RecombinaseRNA HelicasesSyndromeBRIP1 protein, humanDDX11 protein, humanDEAD-box RNA HelicasesDNA HelicasesFanconi Anemia Complementation Group ProteinsRAD51 protein, humanRad51 RecombinaseRNA HelicasesTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID32855419
PMCPMC7452896
OpenAlexW3081246627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.